Christoph Wanner
Elite in Type 2 Diabetes (T2D)

Christoph Wanner

Oberduerrbacher Str. 6, 
Wuerzburg, BY, DE 
Elite in Type 2 Diabetes (T2D)
Oberduerrbacher Str. 6, 
Wuerzburg, BY, DE 
OverviewLocationsClinical Research

Overview

Christoph Wanner practices in Wuerzburg, Germany. Mr. Wanner is rated as an Elite expert by MediFind in the treatment of Type 2 Diabetes (T2D). His top areas of expertise are Fabry Disease, Type 2 Diabetes (T2D), Chronic Kidney Disease, Heart Failure, and Kidney Transplant.

His clinical research consists of co-authoring 641 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 179 articles in the study of Type 2 Diabetes (T2D).

Gender
Male

Locations

Oberduerrbacher Str. 6, Wuerzburg, BY 97080, Germany
Other Locations
Josef Schneider Str. 2, Wuerzburg, BY 97080, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients With IgA Nephropathy at Risk of Progressive Loss of Renal Function
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients With IgA Nephropathy at Risk of Progressive Loss of Renal Function
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2024
Intervention Type: Drug
Study Drug: Atrasentan
Study Phase: Phase 3
An Open Label Study of the Safety and Efficacy of PRX-102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa)
An Open Label Study of the Safety and Efficacy of PRX-102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa)
Enrollment Status: Completed
Publish Date: September 13, 2023
Intervention Type: Biological
Study Phase: Phase 3
A Randomized, Double Blind, Active Control Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function in Patients With Fabry Disease Previously Treated With Agalsidase Beta
A Randomized, Double Blind, Active Control Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function in Patients With Fabry Disease Previously Treated With Agalsidase Beta
Enrollment Status: Completed
Publish Date: September 13, 2023
Intervention Type: Biological
Study Drugs: PRX-102 (Pegunigalsidase Alfa), Agalsidase Beta
Study Phase: Phase 3
View 2 Less Clinical Trials

640 Total Publications

Correction: Frequent hemodialysis versus standard hemodialysis for people with kidney failure: Systematic review and meta-analysis of randomized controlled trials.
Correction: Frequent hemodialysis versus standard hemodialysis for people with kidney failure: Systematic review and meta-analysis of randomized controlled trials.
Journal: PloS one
Published: September 15, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Wanner's expertise for a condition
ConditionClose
View All 16 Advanced Conditions
View All 36 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile